Chitosan coating of anionic liposomes containing sumatriptan succinate: a candidate for nasal administration

Document Type : Research Paper

Authors

1 Molecular and Cell biology Research Center, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran

2 Department of Pharmacology, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran

3 Department of Medical Nanotechnology, School of Advanced Technologies in Medicine, Mazandaran University of Medical Sciences, Sari, Iran

4 Toxoplasmosis Research Center, Communicable Diseases Institute, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran

Abstract

Objective(s): Sumatriptan is a routine medication in the treatment of migraine and cluster headache that is generally given by oral or parental routes. However, a substantial proportion of patients suffer severe side effects. Nasal administration is significantly effective in case of oral administration of drug gives an undesirable side effect. So, the purpose of the present study was to develop intranasal delivery systems of Sumatriptan succinate using nanoliposomes as container of a water-soluble drug and chitosan as a mucoadhesive polymer.
Materials and Methods: Liposomal formulations containing Sumatriptan as well as chitosan-coated liposomal formulations with different phospholipids and different concentrations were prepared. The formulations were evaluated for their physicochemical properties, stability and Cytotoxicity on BEAS-2B cells.
Results: The prepared liposomal formulations coated with chitosan containing Sumatriptan had a size range of 165±9.4to 258±6.4 nm, and the surface charge of the obtained formulations was measured between 32±6 and 40±5 mV. Also, the encapsulation efficiency of the formulations was also observed between 14.2±2.7% and 19±3.4%. Based on the obtained results of physicochemical studies, liposomes F2 was also tested for stability and toxicity and showed that the F2 liposomes retained its physicochemical properties for up to 3 months. Finally, the toxicity test of the mentioned formulation showed relatively low toxicity on BEAS-2B cells.
Conclusion: In the presents study, stable liposomal formulations coated with chitosan containing Sumatriptan were prepared and studied. Based on the obtained, these formulations can be used in preclinical and animal studies for the nasal administration of Sumatriptan.
 

Keywords

References

1.Silberstein SD. A review of clinical safety data for sumatriptan nasal powder administered by a breath powered exhalation delivery system in the acute treatment of migraine. Expert Opin Drug Saf. 2018; 17(1): 89-97.
2.Kim J-S, Kim M-S, Baek I-h. Enhanced Bioavailability of Tadalafil after Intranasal Administration in Beagle Dogs. Pharmaceutics. 2018;10(4):187.
3.Davis SS, Illum L. Absorption Enhancers for Nasal Drug Delivery. Clin Pharmacokinet. 2003 ;42(13): 1107-1128.
4.Jakate A, Boinpally R, Butler M, Lu K, McGeeney D, Periclou A. Evaluation of the Pharmacokinetic Interaction of Ubrogepant Coadministered With Sumatriptan and of the Safety of Ubrogepant With Triptans. Headache: J Headache Pain. 2020; 60(7): 1340-1350.
5.Evans RW. Migraine: A Question and Answer Review. Med clin n am. 2009;93(2):245-262.
6.Kumar A, Naik PK, Pradhan D, Ghosh G, Rath G. Mucoadhesive formulations: innovations, merits, drawbacks, and future outlook. Pharm Dev Technol. 2020; 25(7): 797-814.
7.Ugwoke MI, Agu RU, Verbeke N, Kinget R. Nasal mucoadhesive drug delivery: Background, applications, trends and future perspectives. Adv Drug Deliver Rev. 2005; 57(11): 1640-1665.
8.M. Ways TM, Lau WM, Khutoryanskiy VV. Chitosan and Its Derivatives for Application in Mucoadhesive Drug Delivery Systems. Polymers. 2018; 10(3): 267.
9.Shim S, Yoo HS. The Application of Mucoadhesive Chitosan Nanoparticles in Nasal Drug Delivery. Mar Drugs. 2020; 18(12): 605.
10.Hezarjaribi HZ, Soosaraei M, Fakhar M, Akhtari J, Rafiei A, Jorjani ON. Preparation and characterization of a nanoliposomal vaccine of pcLACK candidate against cutaneous leishmaniasis. Infect Disord Drug Targets. 2020.
11.Mehravaran A, Rezaei Nasab M, Mirahmadi H, Sharifi I, Alijani E, Nikpoor AR, Akhtari J, Hojatizade M. Immunogenicity and protection effects of cationic liposome containing imiquimod adjuvant on leishmaniasis in BALB/c mice. Iran J Basic Med Sci. 2019; 22(8): 922-931.
12.Akhtari J, Rezayat SM, Teymouri M, Alavizadeh SH, Gheybi F, Badiee A, Jaafari, M. Targeting, bio distributive and tumor growth inhibiting characterization of anti-HER2 affibody coupling to liposomal doxorubicin using BALB/c mice bearing TUBO tumors. Int J Pharmaceut. 2016; 505(1): 89-95.
13.Hamedinasab H, Rezayan AH, Mellat M, Mashreghi M, Jaafari MR. Development of chitosan-coated liposome for pulmonary delivery of N-acetylcysteine. Int J Biol Macromol. 2020; 156: 1455-1463.
14.Amin M, Badiee A, Jaafari MR. Improvement of pharmacokinetic and antitumor activity of PEGylated liposomal doxorubicin by targeting with N-methylated cyclic RGD peptide in mice bearing C-26 colon carcinomas. Int J Pharmaceut. 2013; 458(2): 324-333.
15.Akhtari J, Faridnia R, Kalani H, Bastani R, Fakhar M, Rezvan H, Beydokhti AK. Potent in vitro antileishmanial activity of a nanoformulation of cisplatin with carbon nanotubes against Leishmania major. J Glob Antimicrob Re. 2019; 16: 11-6.
16.Seo JJ, Park J, Bae MH, Lim M-s, Seong SJ, Lee J, Park SM, Lee HW, Yoon Y. Rapid determination of sumatriptan in human plasma by ultra-performance liquid chromatography–tandem mass spectrometry and its application to clinical pharmacokinetic study. J Chromatogr B. 2013; 919-920: 38-42.
17.Ge Z, Tessier E, Neirinck L, Zhu Z. High performance liquid chromatographic method for the determination of sumatriptan with fluorescence detection in human plasma J Chromatogr B. 2004; 806(2): 299-303.
18.Mehravaran A, Nasab MR, Mirahmadi H, Sharifi I, Alijani E, Nikpoor AR, Akhtari J. Protection induced by Leishmania Major antigens and the imiquimod adjuvant encapsulated on liposomes in experimental cutaneous leishmaniasis. Infect Genet Evol. 2019; 70: 27-35.
19.Gheybi F, Alavizadeh SH, Rezayat SM, Zendedel E, Jaafari M. Chemotherapeutic activity of Silymarin combined with doxorubicin liposomes in 4T1 breast cancer cells. Nanomed Res J. 2019; 4(1): 29-34.
20.Fan Y, Marioli M, Zhang K. Analytical characterization of liposomes and other lipid nanoparticles for drug delivery. J Pharmaceut Biomed. 2021; 192: 113642.
21.Cuomo F, Cofelice M, Venditti F, Ceglie A, Miguel M, Lindman B, Lopez F. In-vitro digestion of curcumin loaded chitosan-coated liposomes. Colloid Surface B. 2018; 168: 29-34.
22.Salade L, Wauthoz N, Vermeersch M, Amighi K, Goole J. Chitosan-coated liposome dry-powder formulations loaded with ghrelin for nose-to-brain delivery. Eur J Pharm Biopharm. 2018; 129: 257-266.
23.Alshraim MO, Sangi S, Harisa GI, Alomrani AH, Yusuf O, Badran MM. Chitosan-Coated Flexible Liposomes Magnify the Anticancer Activity and Bioavailability of Docetaxel: Impact on Composition. Molecules. 2019; 24(2): 250.
24.Maeda N, Ikeda K, Matsumoto M, Namba Y. Advanced lipid technology. J Lipos Res. 2017; 27(3): 221-227.
25.Gregoriadis G. Liposomes in Drug Delivery: How It All Happened. Pharmaceutics. 2016; 8(2): 19.
26.Hung W-C, Lee M-T, Chen F-Y, Huang HW. The Condensing Effect of Cholesterol in Lipid Bilayers. Biophys J. 2007; 92(11): 3960-3967.
27.Ali MH, Moghaddam B, Kirby DJ, Mohammed AR, Perrie Y. The role of lipid geometry in designing liposomes for the solubilisation of poorly water soluble drugs. Int J Pharmaceut. 2013; 453(1): 225-232.
28.Li F, Lin J-y, Li Y-w, Wang L-z, Shi H-c, Liu M-q. Preparation and Stability of Ganciclovir Liposome. J-Taiyuan Uni Of Tech. 2008; 39(2): 196.
Nanomedicine Journal
Volume 8, Issue 2
April 2021
Pages 132-139

Files

Share

How to cite

Statistics